NMTC

NeuroOne Medical Technologies Corporation Common Stock

NMTC
Closed
$2.75
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

NeuroOne Medical Technologies Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Eden Prairie, Minnesota and currently employs 18 full-time employees. The company went IPO on 2012-11-09. NeuroOne Medical Technologies Corporation is a medical technology company. The company is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The company may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.
Country

US

CEO

Mr. David Rosa

IPO date

2012

Employees

18

ISIN

US64130M3088

Website

nmtc1.com

Key stats

Open

$2.98

Volume

34.07K

Market cap

$26.02M

Prev. close

$2.75

Impl / hst vl

-

Open interest

$0.00

$2.61

Day’s Range

$2.98

$0.61

52W Range

$5.40

Valuation

55
Valuation score
Fairly Valued
P/E
-
P/S
2.68
P/B
4.84
Current ratio
4.38
Debt / Equity
-0.39
ROE
-98.33%
Gross margin
53.81%
Income growth
45.05%
FCF growth
-56.69

Analysts estimates

Consensus rating
Buy

The average rating from top 5 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$10.13
The top 5 analysts forecasts that 12-month price may increase by 268.44%, with a low of $8.08 and a high of $13.65
$8.08
Low
$10.13
Avg
$13.65
High
Current price

Earnings

Q1 ‘26 revenue
$2.39M
Q1 ‘26 net income
-$2.09M
Revenue
Net income
Previous EPS
-$0.25
Estimate EPS
-$0.22
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply